Disclosed is the use of alisporivir in the manufacture of a medicament for the treatment of a Hepatitis C virus genotype 1 infected patient, wherein the medicament is adapted for administration in combination with standard of care； wherein the patient is a relapser； wherein the medicament is adapted for administration of alisporivir during an initial phase in an amount of about 600 mg twice per day, followed by a second phase in an amount of about 600 to about 1000 mg once per day； and wherein the standard of care is a combination of interferon with ribavirin.
